 |
245 Diseases |  |
54 Trials |
|
54 Trials |  |
1419 News |  |
| «12...9101112131415161718192021 |
- peripheral blood stem cell transplantation / National Cancer Institute
Gene therapy: Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma (clinicaltrials.gov) - Jan 15, 2013
P=N/A, N=13, Not yet recruiting, Sponsor: Fred Hutchinson Cancer Research Center
- carmustine / Generic mfg.
Trial termination: O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell Lymphoma (clinicaltrials.gov) - Jan 9, 2013
P1, N=20, Terminated, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated
- carmustine / Generic mfg.
Trial initiation date: O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell Lymphoma (clinicaltrials.gov) - Jan 9, 2013
P1, N=20, Terminated, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated Initiation date: Jan 1999 --> Apr 1999
- Rituxan (rituximab) / Roche
Trial withdrawal: S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia (clinicaltrials.gov) - Jan 8, 2013
P2, N=0, Withdrawn, Sponsor: Southwest Oncology Group
Initiation date: Jan 1999 --> Apr 1999 Completed --> Withdrawn
- Rituxan (rituximab) / Roche
Enrollment change: S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia (clinicaltrials.gov) - Jan 8, 2013
P2, N=0, Withdrawn, Sponsor: Southwest Oncology Group
Completed --> Withdrawn N=50 --> 0
- cyclophosphamide / Generic mfg., paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial termination: S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer (clinicaltrials.gov) - Jan 1, 2013
P3, N=602, Terminated, Sponsor: Southwest Oncology Group
N=50 --> 0 Completed --> Terminated; poor accrual
- cyclophosphamide / Generic mfg., paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Enrollment change: S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer (clinicaltrials.gov) - Jan 1, 2013
P3, N=602, Terminated, Sponsor: Southwest Oncology Group
Completed --> Terminated; poor accrual N=1000 --> 602
- Enrollment closed, Gene therapy: Gene Therapy-Treated Stem Cells in Treating Patients Undergoing Stem Cell Transplant for Intermediate-Grade or High-Grade AIDS-Related Lymphoma (clinicaltrials.gov) - Dec 17, 2012
P=N/A, N=10, Active, not recruiting, Sponsor: City of Hope Medical Center
N=1000 --> 602 Recruiting --> Active, not recruiting
- Simulect (basiliximab) / Novartis, 90Y basiliximab - National Cancer Institute / Bethesda
Enrollment open: Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma (clinicaltrials.gov) - Nov 19, 2012
P1/2, N=64, Recruiting, Sponsor: City of Hope Medical Center
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Intron A (interferon ?-2b) / Merck (MSD), Biogen
Trial initiation date: Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma (clinicaltrials.gov) - Nov 13, 2012
P3, N=312, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Initiation date: Apr 1994 --> Jul 1994
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial withdrawal: Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease (clinicaltrials.gov) - Oct 8, 2012
P2, N=0, Withdrawn, Sponsor: Masonic Cancer Center, University of Minnesota
Initiation date: Apr 1994 --> Jul 1994 Terminated --> Withdrawn
- Neulasta (pegfilgrastim) / Roche
New P2 trial, Metastases: Dacarbazine and Carmustine in Metastatic Melanoma (clinicaltrials.gov) - Sep 23, 2012
P2, N=35, Recruiting, Sponsor: Western Regional Medical Center
- Trial initiation date: CALGB 51101: Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma (clinicaltrials.gov) - Sep 20, 2012
P2, N=160, Recruiting, Sponsor: Cancer and Leukemia Group B
Terminated --> Withdrawn Initiation date: Jan 2012 --> Sep 2012
- Enrollment open: CALGB 51101: Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma (clinicaltrials.gov) - Sep 20, 2012
P2, N=160, Recruiting, Sponsor: Cancer and Leukemia Group B
Initiation date: Jan 2012 --> Sep 2012 Not yet recruiting --> Recruiting
- temozolomide / Generic mfg., erlotinib / Generic mfg., carmustine / Generic mfg.
Trial completion: Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme (clinicaltrials.gov) - Sep 19, 2012
P2, N=110, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment change: Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202) (clinicaltrials.gov) - Aug 14, 2012
P2/3, N=30, Terminated, Sponsor: Medical College of Wisconsin
Active, not recruiting --> Completed N=75 --> 30
- New P2 trial: Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation (clinicaltrials.gov) - Jul 29, 2012
P2, N=10, Completed, Sponsor: Washington University School of Medicine
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, Amsidine (amsacrine) / Kyowa Kirin
Trial completion: Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 28, 2012
P3, N=500, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=75 --> 30 Active, not recruiting --> Completed
- | carmustine / Generic mfg.
Trial completion: Radiation Therapy in Treating Patients With Brain Cancer (clinicaltrials.gov) - Jun 28, 2012
P3, N=212, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion: Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies (clinicaltrials.gov) - Jun 18, 2012
P2, N=93, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment closed, Post-transplantation: Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak) (clinicaltrials.gov) - Apr 10, 2012
P2, N=45, Active, not recruiting, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- trabedersen (OT-101) - Autotelic, Oncotelic / Dragon Overseas JV
Trial termination: SAPPHIRE: Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma (clinicaltrials.gov) - Mar 27, 2012
P3, N=27, Terminated, Sponsor: Isarna Therapeutics GmbH
Active, not recruiting --> Terminated; Unable to recruit the projected patient number. All analyses are descriptive, only.
- trabedersen (OT-101) - Autotelic, Oncotelic / Dragon Overseas JV
Enrollment change: SAPPHIRE: Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma (clinicaltrials.gov) - Mar 27, 2012
P3, N=27, Terminated, Sponsor: Isarna Therapeutics GmbH
All analyses are descriptive, only. N=180 --> 27
- Avastin (bevacizumab) / Roche
Enrollment closed: Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma (clinicaltrials.gov) - Mar 25, 2012
P2, N=20, Active, not recruiting, Sponsor: University of California, Davis
N=180 --> 27 Recruiting --> Active, not recruiting
- Rituxan (rituximab) / Roche
Trial completion: Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Mar 22, 2012
P2, N=44, Completed, Sponsor: University of Nebraska
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- irinotecan / Generic mfg., carmustine / Generic mfg.
Enrollment change: Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors (clinicaltrials.gov) - Mar 12, 2012
P1, N=21, Completed, Sponsor: Darell D. Bigner
Active, not recruiting --> Completed N=41 --> 21
- irinotecan / Generic mfg., carmustine / Generic mfg.
Trial completion: Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors (clinicaltrials.gov) - Mar 12, 2012
P1, N=21, Completed, Sponsor: Darell D. Bigner
N=41 --> 21 Active, not recruiting --> Completed
- | Rituxan (rituximab) / Roche, Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
New P1/2 trial: Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma (clinicaltrials.gov) - Feb 22, 2012
P1/2, N=40, Completed, Sponsor: M.D. Anderson Cancer Center
- | New P2 trial: CALGB 51101: Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma (clinicaltrials.gov) - Jan 16, 2012
P2, N=160, Recruiting, Sponsor: Cancer and Leukemia Group B
- peripheral blood stem cell transplantation / National Cancer Institute
Biomarker, Trial termination, Metastases: S9901 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Men With Stage III or Stage IV Hodgkin's Disease (clinicaltrials.gov) - Jan 11, 2012
P3, N=11, Terminated, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Terminated; poor accrual
- Enrollment change: High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors (clinicaltrials.gov) - Jan 10, 2012
P=N/A, N=174, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Terminated; poor accrual N=530 --> 174
- Enrollment closed: High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors (clinicaltrials.gov) - Jan 10, 2012
P=N/A, N=174, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
N=530 --> 174 Recruiting --> Active, not recruiting
- New P2 trial: Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match (clinicaltrials.gov) - Dec 26, 2011
P2, N=1, Terminated, Sponsor: Texas Oncology Cancer Center
- Rituxan (rituximab) / Roche, Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Enrollment closed: Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation (clinicaltrials.gov) - Dec 18, 2011
P2, N=50, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Simulect (basiliximab) / Novartis, 90Y basiliximab - National Cancer Institute / Bethesda
New P1/2 trial: Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma (clinicaltrials.gov) - Nov 20, 2011
P1/2, N=64, Recruiting, Sponsor: City of Hope Medical Center
- Campath (alemtuzumab) / Sanofi
Trial termination: Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma (clinicaltrials.gov) - Nov 3, 2011
P2, N=27, Terminated, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Completed --> Terminated; Slow Accrual.
- cyclophosphamide / Generic mfg., etoposide IV / Generic mfg., carmustine / Generic mfg.
Enrollment closed: Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma (clinicaltrials.gov) - Oct 13, 2011
P=N/A, N=25, Active, not recruiting, Sponsor: City of Hope Medical Center
Completed --> Terminated; Slow Accrual. Recruiting --> Active, not recruiting
- mycophenolate mofetil / Generic mfg., sirolimus / Generic mfg.
Trial termination: Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT (clinicaltrials.gov) - Oct 10, 2011
P2, N=3, Terminated, Sponsor: Stanford University
Recruiting --> Active, not recruiting Active, not recruiting --> Terminated; Low accrual
- mycophenolate mofetil / Generic mfg., sirolimus / Generic mfg.
Enrollment change: Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT (clinicaltrials.gov) - Oct 10, 2011
P2, N=3, Terminated, Sponsor: Stanford University
Active, not recruiting --> Terminated; Low accrual N=38 --> 3
- Trial completion: Combination Chemotherapy With or Without Total-Body Irradiation Followed By Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma (clinicaltrials.gov) - Sep 19, 2011
P2, N=60, Completed, Sponsor: City of Hope Medical Center
N=38 --> 3 Active, not recruiting --> Completed
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment closed, IO biomarker: Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant (clinicaltrials.gov) - Sep 1, 2011
P2, N=48, Active, not recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion: Rituxan and BEAM With Autologous Peripheral Blood Progenitor Transplant for Indolent Lymphoma (clinicaltrials.gov) - Aug 31, 2011
P1/2, N=32, Completed, Sponsor: University of Nebraska
Recruiting --> Active, not recruiting Active, not recruiting --> Completed